Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MZ-004 for Chronic Total Occlusions (TOSCA-5)
NCT01753180Phase 2Completed
- Sponsor
- Matrizyme Pharma
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Therapeutic Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of collagenase clostridium histolyticum in Chronic total coronary occlusion (CTO), sponsored by Matrizyme Pharma. Started Apr 2014; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Chronic total coronary occlusion (CTO)
Beyond the preview
Go deeper on NCT01753180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01753180.